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healthy controls. Patients with community-acquired pneu-
monia were more often infected with adenovirus and respi-
ratory syncytial virus as compared with the other LRTI pa-
tients (p = 0.046 and 0.0009, respectively).  Conclusions: 
There is a high incidence of single and multiple viral infec-
tions in LRTI patients requiring hospitalization. The data in-
dicate the need for regular virus diagnosis and the develop-
ment of point of care tools that enables a fast diagnosis of 
the most common viruses and bacteria. The data also imply 
the need to consider antiviral therapy in positive LRTI cases. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Lower respiratory tract infection (LRTI) is the most 
frequent cause of hospitalization worldwide  [1–7] . Over 
the past decade, several studies aimed to define param-
eters that allow the distinction between bacterial and vi-
ral infections causing LRTI. The methods used included 
polymerase chain reaction (PCR), procalcitonin determi-
nation and other clinical information  [8–15] . However, 
the information obtained by medical history, physical ex-
amination, routine laboratory parameters and chest radi-
ography is not sufficient for a clear differential diagnosis 
of the cause of LRTI. Virus diagnosis is difficult as the 
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 Abstract 
 Background: Lower respiratory tract infection (LRTI) often 
leads to hospitalization, and it was indicated that causative 
viral infections are underestimated.  Objectives: It was our 
aim to compare the frequency of 8 relevant viruses in 109 
hospitalized LRTI patients and 144 healthy controls.  Meth-
ods: Virus infection was determined by seroconversion and 
ELISA for anti-virus antibodies in repeated serum samples. 
Bacterial infection was diagnosed in respiratory specimens, 
blood cultures and urine.  Results: The LRTI patient cohort 
consisted of 49 patients with community-acquired pneumo-
nia, 30 patients with acute bronchitis and 30 chronic ob-
structive pulmonary disease patients with acute exacerba-
tion. Viral infection was detected in 89 (82%) LRTI patients 
compared with 32 (22%) in healthy controls (relative risk 3.42, 
95% confidence interval 2.48–4.72; p  ! 0.0001). The most fre-
quent viral pathogens were: influenza B (23%), adenovirus 
(16%) and parainfluenza virus 3 (12%). Importantly, infec-
tions with more than 1 virus were detected in 63% (n = 57) of 
LRTI patients with viral infection, which represents 52% of all 
LRTI patients. No multiple virus infection was detected in the 
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samples obtained may not be taken from an area in which 
the virus is present, and sampling with various methods 
was suggested by a recent study  [16] . Rapid point of care 
diagnosis and differentiation of viral and bacterial infec-
tions in LRTI patients will improve patient management 
and help the decision to treat with antibiotics, or with 
new antiviral drugs, and in order to prevent the virus 
from spreading, such data might implement infection 
control.
 Data of viral infection incidence in LRTI patients are 
scarce, and less than 70 publications addressed this issue 
during the past 5 years. All studies clearly indicated that 
viral infections in LRTI patients are underestimated even 
though it is the cause of more than 50% of hospitaliza-
tions. Unfortunately, most of these studies only investi-
gated the presence of a single virus in a specific subset of 
LRTI patients. The fact that viral infections are difficult 
to treat should not lead to neglecting the diagnosis. Viral 
LRTI in early infancy was indicated to induce a predispo-
sition to develop wheezing and asthma  [17] . Viral infec-
tion is assumed to precede bacterial infections and may 
generate the environment for bacterial superinfections 
 [15, 18, 19] . There is also evidence that viral infections 
make the lower respiratory tract more susceptible for 
fungal infections  [20] . These findings indicate the need 
to develop new point of care tools for the diagnosis of vi-
ral infections and the differentiation from bacterial infec-
tions or the diagnosis of viral/bacterial coinfections. The 
argument that viral infections are difficult to treat still 
applies for most viruses; however, there are newly devel-
oped drugs, especially monoclonal antibodies that are vi-
rus specific and can be used to treat or even prevent viral 
infections  [21, 22] .
 A further concern in LRTI patients is the occurrence 
of unwanted development of antibiotic-resistant bacteria 
strains. Bacterial infection is documented in approxi-
mately 25% of LRTI patients; however, the majority of 
LRTI patients are treated with antibiotics  [5, 23, 24] . De-
spite therapy with antibiotics, the mortality and morbid-
ity associated with LRTI is relevant and might be due to 
colonization with nonbacterial or antibiotic-resistant mi-
croorganisms  [2, 6] . LRTI caused by nonbacterial infec-
tion cannot be treated by antibiotic therapy, and for this 
condition, the use of antibiotics is known to lead to the 
occurrence of antibiotic resistance in clinically relevant 
bacteria  [25] .
 The aim of this study was to determine the incidence 
of serological markers for the 8 most common communi-
ty-acquired viral infections in a well-characterized LRTI 
population.
 Material and Methods 
 Setting and Study Population 
 Data from a prospective monocentric trial including a total of 
218 repeated serum samples obtained from 109 LRTI patients 
were analyzed. In brief, the main objective of the study was to 
evaluate procalcitonin-guided antibiotic de-escalation in LRTI as 
compared with usual care. The study took place at the emergency 
ward of the University Hospital Basel, Basel, Switzerland. The 
analysis of the incidence of virus infection by serology in the study 
population was a predefined secondary endpoint of the protocol. 
The study was approved by the institutional review board of 
Beider Basel. Written informed consent was obtained from all in-
cluded patients or their legal representatives.
 Diagnostic Criteria 
 The diagnosis of LRTI was established on the basis of clinical 
investigations, according to the following definitions: communi-
ty-acquired pneumonia (CAP) was defined by a new infiltrate on 
chest X-ray together with cough, sputum production, dyspnea, 
fever ( 1 38.0   °   C), auscultatory abnormal breath sounds and rales. 
An additional criteria for LRTI was leukocytosis ( 1 10  ! 10 9 
cells/l) or leukopenia ( ! 4  ! 10 9 cells/l)  [26, 27] . Acute bronchitis 
was defined by onset of cough 2–14 days (with or without sputum) 
prior to hospitalization in the absence of other lung disease or 
lung infiltrates (chest X-ray) according to a standard definition 
 [28] . Acute exacerbation of chronic obstructive pulmonary dis-
ease (COPD) was defined as increased sputum, discolored spu-
tum and/or dyspnea and a forced expiratory volume in 1 s/forced 
vital capacity ratio  ! 70% according to GOLD guidelines  [29] .
 Baseline Assessment and Follow-Up  
 On admission, all patients were assessed according to a stan-
dardized protocol, including blood sampling for white blood 
counts, C-reactive protein, procalcitonin, blood cultures and a 
chest X-ray. The same blood samples were used for serological 
testing of antigens and/or antibodies for adenovirus, influenza A 
virus, influenza B virus, parainfluenza virus type 1, parainflu-
enza virus type 2, parainfluenza virus type 3, respiratory syncy-
tial virus (RSV), enterovirus (coxsackie B5 pool, echovirus), and 
for  Mycoplasma pneumoniae, by an EIA screening kit (Anibiotech 
Orgenium Laboratories, Vantaa, Finland). Virus serology was 
considered positive if immunoglobulin (Ig)M was above estab-
lished levels, and/or if seroconversion of IgG occurred comparing 
acute and convalescence serum samples, and/or in case very high 
levels of IgG were detected.
 In patients presenting an infiltrate on chest X-ray, a search for 
 Legionella pneumophilia antigen in urine was routinely per-
formed. Sputum was collected cultures according to Murray’s cri-
teria for microbiological analysis. Bronchoalveolar lavage was 
performed and used for culture and/or PCR for  L. pneumophilia, 
 Chlamydia pneumoniae and  M. pneumoniae. Control serum sam-
ples were collected from 144 healthy controls within the same 
period.
 All tests were performed on admission and repeated at follow-
up examinations after 2–3 weeks.
 Laboratory Parameters and Definitions 
 White blood cell differentiation and counts were determined 
by flow cytometry according to standard procedures (MaxM; 
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Coulter Beckmann, Krefeld, Germany). C-reactive protein was 
determined by turbidimetric assay using polyclonal goat anti-hu-
man antibodies (Tina-Quant  , Hitachi 717; Roche Diagnostics 
GmbH, Mannheim, Germany). Procalcitonin levels were deter-
mined by immunoluminometric assay (Kryptor  PCT; Brahms 
Diagnostica, Berlin, Germany).
 The cutoff values of IgM and IgG levels were determined for 
each viral antigen in serum samples of 30 healthy controls (data 
not shown). IgM-positive samples were retested after removal of 
IgG and rheumatoid factor by IgM sample preparation reagent 
(Anibiotech Orgenium Laboratories).
 Seroconversion was defined as change from negative to posi-
tive IgG or IgM levels, or by a  1 4-fold increase in the respective 
Ig level comparing 2 serum samples of each patient. Seroconver-
sion was determined by complement fixation test in samples of 10 
patients for all above mentioned microorganisms according to the 
manufacturer’s instructions (Virion, Rueschlikon, Switzerland). 
Samples for the complement fixation test were titrated from 1 to 
64 values to the IgG EIA. An increase of  6 50% in IgG EIA test 
absorbance value or EIA was equal to a 4-fold titer rise in the 
complement fixation test. The percentage of EIA units was calcu-
lated as: [(difference EIA unit 2nd sample – EIA unit 1st sample) 
 ! 100]/(EIA unit 1st sample).
 The definition for ‘positive’ IgM and IgG levels was based on 
data obtained in serum samples of 30 healthy controls by the use 
of purified antigens in an EIA test system. Values are presented as 
enzyme immunoassay unit. Enterovirus data were based on a 
pool of antigens specific for coxsackievirus B5 Faulkner strain 
and echovirus 9 isolates. For influenza A, we detected an antigen 
pool specific for the following strains: A/Beijing/262/95 (H1N1), 
Panama/2007/99 (H3N2), New Caledonia/20/99 IVR 116 (H1N1), 
and Kiev/301/94 (H3N2) ( table 1 ).
 Statistical Analysis 
 Discrete variables are expressed as counts, and continuous 
variables as means  8 SD or median (interquartile range). The 
4-field   2 test was used to analyze frequency distribution for each 
virus species between the patient groups. A p value  ! 0.05 was de-
fined as significant. Data were analyzed using Statistical Package 
for Social Sciences (SPSS Inc., Chicago, Ill., USA; version 15 for 
Windows) and Sigma Plot (version 10 for Windows). The authors 
held and analyzed all data.
 Results 
 Patient Characteristics 
 The mean age of the 109 LRTI patients was 64.8 years 
(range 23–94) including 63 males and 46 females. Final 
diagnoses were: 49 patients with CAP, 30 COPD patients 
with acute exacerbations, and 30 patients with acute 
bronchitis. Cough was reported by all patients, 85 pa-
tients (73%) produced sputum, 61 patients (52%) had dis-
colored sputum and 78 patients (67%) suffered from dys-
pnea. The mean body temperature of all patients on ad-
mission was 37.7   °   C ( table 2 ). Leukocyte counts in CAP 
(10.2  ! 10 9 /l) and acute exacerbation of COPD (11.2  ! 
10 9 /l) patients were significantly higher compared with 
LRTI patients with acute bronchitis (8.7  ! 10 9 /l; p  ! 
0.02). The average C-reactive protein level in CAP pa-
tients (171 mg/ml) was significantly higher compared 
with all other groups (p  ! 0.05). Similarly, procalcitonin 
Table 1.  Criteria and cutoff values for virus serology
Type of antigens used in the EIA tests IgG high positive IgM positive
Adenovirus adenovirus type 6 ≥130 ≥30
Enterovirus B5 Faulkner strain and echovirus 9
A/Beijing/262/95 (H1N1), Panama/2007/99 (H3N2) 
≥100 ≥30
Influenza A virus New Caledonia/20/99 IVR 116 (H1N1), Kiev/301/94 (H3N2) ≥100 ≥30
Influenza B virus Hong Kong 5/72 ≥100 ≥30
Parainfluenza virus type 1 Sendai C35 strain ≥100 ≥30
Parainfluenza virus type 2 Greer strain ≥100 ≥30
Parainfluenza virus type 3 C-243 strain ≥100 ≥30
RSV Long strain ≥100 ≥30
M. pneumoniae strain FH ≥100 ≥35
T he definition for ‘positive’ IgM and IgG levels was based on data obtained in serum samples of 30 healthy controls by the use of 
purified antigens in an EIA test system. Values are presented as enzyme immunoassay unit. Enterovirus data are based on a pool of 
antigens specific for coxsackievirus B5 Faulkner strain and echovirus 9 isolates. For influenza A, we detected an antigen pool spe-
cific for the following strains: A/Beijing/262/95 (H1N1), Panama/2007/99 (H3N2), New Caledonia/20/99 IVR 116 (H1N1), and 
Kiev/301/94 (H3N2).
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levels in CAP patients (4.5  8 1.5 ng/ml) were significant-
ly higher as compared with all other groups (p  ! 0.01). All 
patient characteristics and clinical parameters are sum-
marized in  table 2 .
 Bacteriology and Laboratory Parameters 
 Bacterial infections other than  M. pneumoniae were 
identified in 15 (12.8%) LRTI patients:  Streptococcus 
pneumoniae 4.3% (n = 5), enterobacteria 3.4% (n = 4), 
 Haemophilus influenza 2.6% (n = 3),  Pseudomonas 2.6% 
(n = 3),  Klebsiella 0.8% (n = 1),  M. pneumoniae  0.8% (n = 
1), and  Staphylococcus aureus  0.8% (n = 1). Eight CAP 
patients presented positive blood cultures. Positive bacte-
rial culture in respiratory specimens was found in 12 
COPD patients with exacerbation, in 11 CAP patients and 
in 1 patient with acute bronchitis.
 Viral Serology 
 Compared with the control group, serological analysis 
indicated a significantly higher incidence of viral infec-
tions among LRTI patients – 89 (82%) as compared with 
32 (22%) in healthy controls (p  ! 0.0001). These data in-
dicate a relative risk of 3.73 (95% confidence interval 
2.48–4.72) for viral infection in LRTI patients. The most 
frequent viral pathogens were: influenza B (23%), adeno-
virus (16%) and parainfluenza virus 3 (12%). In addition, 
adenovirus, influenza A and B, parainfluenza 3 and RSV 
were found with a significant higher incidence in LRTI 
patients than in healthy controls ( fig. 1 ). There was no 
significant difference in the incidences of enterovirus in-
fection, and  M. pneumoniae infection was similar in 
LRTI patients and controls ( fig. 1 ). A detailed analysis of 
the incidence of viruses in the 3 LRTI groups is provided 
in  figure 1 .
 Patients with CAP were more often infected with ad-
enovirus and RSV as compared with patients with acute 
bronchitis and acute exacerbations of COPD (p = 0.046 
and 0.0009, respectively) ( fig. 2 ).
 Infections with a single virus were observed in 56 
(51%) LRTI patients as compared with 22 controls (15%; 
p  ! 0.01). Multiple viral infections were detected in 30% 
(n = 33) of the viral infection cases among LRTI patients 
and in none of the healthy controls. No sign of virus or 
 M. pneumoniae infection was found in 28 LRTI patients 
and in the majority of healthy controls ( fig. 3 ).
 Seroconversion for IgG and IgM against any of the 
evaluated viruses was detected in 33 and 34 patients with 
LRTI, respectively. Positive IgM levels for infection with 
virus or  M. pneumoniae was observed in 22 patients on 
the day of hospital admission. Interestingly, none of these 
patients tested positive for IgM 14 days later ( fig. 3 ).
Table 2.  Patient characteristics and clinical parameters
CAP
(n = 49)
Acute bronchitis
(n = 30)
AECOPD
(n = 30)
Total
(n = 109)
Healthy controls
(n = 144)
Median age, years 64.3 [25–91] 59.3 [23–94] 70.5 [50–85] 68 49.6 [19–68]
Males/females 30/19 13/17 20/10 61/48 64/30
Fever 33 (67.3) 9 (30) 8 (26.6) 50 (46.3) 0
Cough 46 (93.9) 30 (100) 30 (100) 106 (97.2) 0
Dyspnea 28 (57.1) 16 (53.3) 30 (100) 74 (67.8) 0
Sputum 32 (65.3) 21 (70) 29 (96.6) 82 (75.2) 0
Discolored sputum 22 (44.9) 11 (36.7) 21 (70) 54 (49.5) 0
Median body temperature, ° C 38.3 [37.4–39.1] 37.3 [36.8–38.0] 37.3 [36.9–38.2] 37.8 [37.0–38.6] –
Median leukocyte counts, !109/l 11 [7.1–18.3] 3 [6–10.1] 3 [7.4–11.6] 9.5 [6.9–13.4] –
Median C-reactive protein, mg/l 160.6 [84.4–242.3] 30.6 [13.3–69.9] 32.9 [9.1–60.0] 65 [21.2–132.4] –
Median procalcitonin, ng/ml 0.728 [0.137–4.141] 0.08 [0.053–0.142] 0.091 [0.069–0.142] 0.130 [0.070–0.686] –
Positive blood cultures 9 (18.4) 0 0 9 (8.3) –
Positive sputum bacteriology 13 (26.5) 1 (3.3) 14 (46.7) 28 (25.7) –
Infiltrate on chest X-ray 49 (100) 0 0 49 (44.9) –
Neoplastic disease 6 (12.2) 1 (3.3) 2 (6.7) 9 (8.2)
Liver disease 5 (10.2) 0 1 (3.3) 6 (5.5)
Congestive heart failure 2 (4.1) 3 (10) 2 (6.7) 7 (6.4)
CVI 3 (6.1) 1 (3.3) 1 (3.3) 5 (4.6)
Renal disease 10 (20.4) 3 (10) 3 (10) 16 (14.7)
Figures in parentheses are percentages; figures in brackets are interquartile ranges. AECOPD = Acute exacerbation of COPD; CVI = cerebrovascular 
insult.
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 Interestingly, all but 1 of 15 LRTI patients presenting 
a positive bacteriology also showed serological signs of 
acute viral infection.
 Discussion 
 This study reports 3 major findings: firstly, compared 
with healthy controls, there is a significant higher inci-
dence of viral infections in LRTI patients. Secondly, in-
fections with more than 1 virus were observed in LRTI 
patients. And thirdly, CAP patients had the highest inci-
dence of adenovirus and RSV infections.
 New studies indicate that the prevalence of bacterial in-
fection in LRTI has been overestimated earlier; on average, 
signs of bacterial infection can be documented in 25% of 
LRTI patients. In our cohort, the incidence of 13% is on the 
lower limit of the range  [5, 23, 24] . We could not find any 
correlation between virus species and bacterial infections 
as has been suggested by other studies  [2, 6, 15, 18, 19] .
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 Increasing evidence suggests that virus infection in 
LRTI patients has been underestimated  [3, 15, 30–35] . 
Our data are in agreement with previous studies which 
were based on virus isolation and culture from bron-
choalveolar lavage samples, PCR results from throat 
swabs and/or serology  [3, 36, 37] . Influenza B virus, ad-
enovirus and parainfluenza virus 3 were the most com-
mon viruses in this LRTI patient cohort. The prevalence 
of influenza virus infection is not surprising as the Euro-
pean Influenza Surveillance Scheme reported a wide-
spread medium level of influenza (A + B) activity in Swit-
zerland during the sampling period (www.eiss.org. EISS: 
Annual report: 2002–2003 influenza season. 2004). Com-
pared with 5 recent studies, the cohort of this study had 
the largest incidence of infections with influenza (A + B), 
parainfluenza 1–3 and RSV  [16, 38–42] . This difference 
might be due to the sampling procedure and the fact that 
most other studies used PCR while we determined IgG 
and IgM levels in repeated serum samples.
 Importantly, infection with more than 1 virus in a sin-
gle patient was underestimated or ignored by earlier stud-
ies. In our cohort of LRTI patients, 30% showed serologi-
cal evidence of multiviral infection. This is nearly double 
the frequency that was reported in other studies  [3, 4, 43, 
44] . The high rate of multiple viral infections could either 
be due to the virus species screened in this study, the pa-
tient-selection criteria, the sampling season, the geo-
graphic localization, or the age of the LRTI patients. To 
exclude the possibility that our data analysis for multiple 
viral infections was caused by cross-reactivity, we further 
analyzed the data for specific viral patterns. However, we 
observed only a random distribution of virus species in 
patients with multiple infections.
 Interestingly, 2 very recent studies which included 550 
and 219 patients, respectively, suggested that viral infec-
tions which are not characteristic for the respiratory tract 
were associated with LRTI; these included herpesviruses, 
cytomegalovirus and coronaviruses  [42, 43] .
 Enterovirus infection in LRTI patients in this study 
was identified with a similar incidence reported in an 
Italian study  [39] , while it was significantly higher com-
pared with the data reported in 2 other studies  [38, 42] . 
This difference may be explained by the test systems or 
by the antigen. The enterovirus antigen used in this study 
was isolated from coxsackievirus B5 and echovirus 9 an-
tigens that are known to cross-react with at least 10 dif-
ferent enterovirus-specific antibodies. Furthermore, a 
cross-reaction of this enterovirus antigen pool with rhi-
noviruses cannot be excluded. There are no data on cox-
sackievirus infection in adult LRTI patients, while cox-
sackievirus was isolated from children with LRTI  [43, 
44] .
 In 28% of LRTI patients, we observed seroconversion 
of influenza viruses, parainfluenza, adenovirus and  M. 
pneumoniae. Unfortunately, there is no comparable study 
to interpret this finding.
 New studies provide evidence that there are options to 
treat viral infections in LRTI patients. Newly developed 
humanized monoclonal antivirus antibodies exist and 
have been used to successfully treat RSV  [21, 22] . Similar 
drugs are in the stage of preclinical testing. One experi-
mental in vitro study suggested that tiotropium bromide 
may also reduce RSV infection in epithelial cells  [45] . 
Available antiviral drugs are: azithromycin for treatment 
of rhinovirus  [46] , chimeric antibodies specific for H5N1 
 [47] , granzyme A for influenza A virus  [48] and the com-
bination of ribavirin with methylprednisolone for para-
influenza virus 3  [49] . These new and upcoming thera-
peutic options put more weight on the demand for point 
of care diagnostic tools in viral and bacterial infections 
in LRTI patients and further strengthen the argument to 
routinely screen viral infection in these patients.
 In conclusion, our data show that infection with single 
and multiple virus species are found at high incidences in 
LRTI patients. Together with other studies, our data im-
ply that the diagnosis of viruses in LRTI patients should 
be performed at the day of admission. This would help in 
patient management, treatment and prevention of virus 
spreading. We are aware that the available diagnostic 
tools for point of care diagnosis are not optimal and we 
are also aware that virus therapy has to be further im-
proved. We hope that the findings of our study can alert 
clinicians regarding the risk of viral infection in LRTI 
patients and stimulate the development of diagnostic 
tools as well as therapeutic strategies. 
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